Mirum Pharmaceuticals' LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and OlderBusiness Wire • 12/13/22
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/09/22
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/09/22
Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLDBusiness Wire • 11/07/22
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 11/02/22
Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022Business Wire • 11/01/22
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver DiseaseBusiness Wire • 10/27/22
Positive Topline Data Announced from Mirum's LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)Business Wire • 10/24/22
Mirum Pharmaceuticals' LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of PediatricsBusiness Wire • 10/18/22
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and OlderBusiness Wire • 10/14/22
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual MeetingBusiness Wire • 10/12/22
Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual MeetingBusiness Wire • 10/05/22
Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common StockBusiness Wire • 08/12/22
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common StockBusiness Wire • 08/09/22
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 08/04/22
Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022Business Wire • 07/28/22
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual MeetingBusiness Wire • 06/24/22